Popular Trials
Behavioral Intervention
Multidisciplinary Care for Rheumatoid Arthritis
This trial will test a new intervention for socioeconomically disadvantaged Hispanic adults with rheumatoid arthritis to see if it improves remission rates. The intervention is based on a partnership between the patient and the extended healthcare team, and includes things like self-management education and technology-based at-home monitoring of symptoms.
Acthar 40 U for Rheumatoid Arthritis
This small study is to investigate the efficacy and safety of Acthar as an adjunct therapy in patients with active rheumatoid arthritis (RA) who have had an inadequate response to disease modifying antirheumatic drugs (DMARDs) and at least 3 biologic agents. An in adequate response is defined as having ≥ 6 tender joints, ≥ 6 swollen joints, plus C-Reactive Protein (CRP) levels and/or erythrocyte sedimentation rate (ESR) of ≥ 1.2 times the upper limit of normal in spite of aggressive treatment, including ≥ 7.5 mg/d prednisone. This will be a 20 week, prospective, multicenter, open-label study conducted at 3-4 university/medical centers and private practice settings in the US. A total of 20 eligible patients will be enrolled and other standard RA therapeutic agents, such as Methotrexate, DMARDs, non-steroidal anti-inflammatory drugs (NSAIDs), pain medications and others will not be discontinued. The primary endpoint will be the percentage of patients with reduction of ≥1.2 points of the Disease Activity Score in 28 joints (DAS-28) score.
Biological DMARD
Anti-TNFα continued perioperatively for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a frequent inflammatory arthritis that can lead to severe joint deformity and often requires orthopaedic surgical interventions. Anti-Tumor Necrosis Factor α (anti-TNFα) are biological disease-modifying antirheumatic drugs (DMARDs) increasingly used in the treatment of rheumatoid arthritis. An increased risk of opportunistic infection was demonstrated in patients treated with those drugs. This observation led many national committees to recommend anti-TNFα suspension in the perioperative period to avoid a raise in the postoperative infection risk in those patients. This approach is not supported by the data available in the current literature and it exposes patients to an increased risk of inflammatory flare ups of their disease during and after anti-TNFα suspension, which can compromise their postoperative rehabilitation and their quality of life. The objective of this prospective randomized multicentric trial is to determine the effect of anti-TNFα suspension in the perioperative period on the postoperative infection risk. Overall, 660 rheumatoid arthritis patients requiring an elective foot or ankle surgery will be randomized into two groups. In the first group, anti-TNFα will be stopped 3 half-lives before the surgery while they will be continued in the second group. The postoperative infection rate will be compared between the two groups. Postoperative complication rates, flares and revision surgeries as well as the functional improvement will be compared. The study hypothesis is that there is no significant difference in the risk of postoperative infection between the two groups. Results from this study will help determine the optimal way to use anti-TNFα in the perioperative period and will therefore improve the quality of life of rheumatoid arthritis patients.
TNF Inhibitor
Stopping TNF Inhibitors for Rheumatoid Arthritis
This trial is testing whether people in remission from RA can stay in remission after discontinuing use of a TNF inhibitor drug, and whether clinical, imaging and immunological measurements can help predict which patients will flare after discontinuing the drug.
Popular Filters
Trials for RA Patients
Behavioural Intervention
Family Physician Consultations for Rheumatoid Arthritis
This trial aims to see if adding a family doctor to a team of rheumatologists can help improve the overall health of people with rheumatoid arthritis. The family doctor will focus on vaccinations, heart
Shared Decision Making Intervention for Rheumatoid Arthritis
This trial will test whether a shared decision making intervention can help reduce disease activity, improve medication adherence, and increase patient knowledge about RA in Veterans Affairs (VA) patients with RA.
Tumor Necrosis Factor (TNF) Blocker
Enbrel with Sofusa DoseConnect for Rheumatoid Arthritis
This trial is testing a new method of giving Enbrel using the SOFUSA system for RA patients who haven't responded well to usual treatments. The SOFUSA system delivers the drug directly through the skin to improve its effectiveness and reduce side effects. Enbrel was the first biological treatment and the first tumour necrosis factor inhibitor approved for use in rheumatic diseases.
Vitamin
Vitamin D + Fish Oil for Health Improvement
This trial is studying whether taking daily dietary supplements of vitamin D3 or omega-3 fatty acids reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Marine and Botanical Oils
combination fish oil and borage seed oil +2 More for Rheumatoid Arthritis
The object of this study is to determine whether treatment of rheumatoid arthritis (RA) with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. This study will also investigate the biochemical, immunological, and molecular mechanism responsible for the therapeutic effects of these fatty acids. Each patient will be followed for eighteen months.
Trials for Osteoarthritis Patients
Vitamin
Vitamin D + Fish Oil for Health Improvement
This trial is studying whether taking daily dietary supplements of vitamin D3 or omega-3 fatty acids reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Joint Replacement
Nexel Total Elbow Replacement for Elbow Osteoarthritis
This trial aims to confirm the safety and effectiveness of the Zimmer Nexel Total Elbow in patients needing their first or a revised elbow replacement. The device replaces damaged parts of the elbow to help reduce pain and improve function. The Zimmer Nexel Total Elbow is used to replace damaged parts of the elbow, primarily in patients with severe elbow pain and joint destruction.
Orthopedic Implant
Ankle Implant for Arthritis
This trial studies a special ankle implant for patients needing ankle surgery. It aims to see how well the implant works in reducing pain and improving function. The implants have been developed to improve stability and longevity, with advancements in design and materials.
Phase 3 Trials
Marine and Botanical Oils
combination fish oil and borage seed oil +2 More for Rheumatoid Arthritis
The object of this study is to determine whether treatment of rheumatoid arthritis (RA) with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. This study will also investigate the biochemical, immunological, and molecular mechanism responsible for the therapeutic effects of these fatty acids. Each patient will be followed for eighteen months.
Disease-modifying antirheumatic drugs (DMARDs)
DMARDs for Rheumatoid Arthritis
This trial is testing whether a certain type of arthritis medication can help predict clinical responses to other types of arthritis medication. All patients will receive a starting dose of the medication being tested, which may be adjusted by the investigator as needed. If a subject becomes intolerant to the medication being tested, the subject will be withdrawn from the study. Data from the study will be collected at the end of the trial.
Janus Kinase (JAK) Inhibitor
Long-Term Safety of Filgotinib for Rheumatoid Arthritis
This trial aims to check the ongoing safety and tolerability of filgotinib, a medication that helps reduce inflammation and pain. The study focuses on people with rheumatoid arthritis who have already used filgotinib in a previous study. Filgotinib works by blocking enzymes that cause inflammation, helping to reduce swelling and pain. Filgotinib has been approved for the treatment of rheumatoid arthritis in adults who respond inadequately to other treatments in Europe and Japan.
Trials With No Placebo
Behavioural Intervention
Family Physician Consultations for Rheumatoid Arthritis
This trial aims to see if adding a family doctor to a team of rheumatologists can help improve the overall health of people with rheumatoid arthritis. The family doctor will focus on vaccinations, heart
Shared Decision Making Intervention for Rheumatoid Arthritis
This trial will test whether a shared decision making intervention can help reduce disease activity, improve medication adherence, and increase patient knowledge about RA in Veterans Affairs (VA) patients with RA.
Tumor Necrosis Factor (TNF) Blocker
Enbrel with Sofusa DoseConnect for Rheumatoid Arthritis
This trial is testing a new method of giving Enbrel using the SOFUSA system for RA patients who haven't responded well to usual treatments. The SOFUSA system delivers the drug directly through the skin to improve its effectiveness and reduce side effects. Enbrel was the first biological treatment and the first tumour necrosis factor inhibitor approved for use in rheumatic diseases.
Procedure
Ulcer Healing Analysis for Inflammatory Bowel Disease
This trial involves taking small pieces of tissue from the colon to study how ulcers heal. It includes patients with inflammatory bowel disease, arthritis, and healthy individuals to compare healing processes. Researchers will examine how genes work and how cells produce energy to understand healing.
View More Related Trials
Frequently Asked Questions
Introduction to ra
What are the top hospitals conducting ra research?
When it comes to revolutionary clinical trials in the field of rheumatoid arthritis (RA), several hospitals are making significant contributions. One such facility is the Altoona Center for Clinical Research located in Duncansville, Pennsylvania. With eight ongoing RA trials, this center is dedicated to pushing the boundaries of treatment options for individuals living with this chronic inflammatory condition. While they may not have conducted any previous trials specifically focused on RA, their commitment and expertise make them an essential player in advancing knowledge and improving patient outcomes.
Another notable institution at the forefront of RA research is Brigham and Women's Hospital situated in Boston, Massachusetts. They currently have five active clinical trials aimed at unraveling new insights into this debilitating disease. Like Altoona Center for Clinical Research, they also do not have a history of past RA trials; however, their renowned reputation as a leading medical center makes them a trusted source for cutting-edge discoveries.
Heading west to Palm Desert, California brings us to Desert Medical Advances where four active RA trials are underway. Although they haven't conducted any historical studies on RA either, their participation demonstrates their dedication towards finding innovative solutions that can alleviate symptoms and improve quality of life for those affected by this autoimmune disorder.
Lincoln's Physician Research Collaboration, LLC also joins the ranks with four ongoing clinical trials focused on rheumatoid arthritis treatment advancements. Similar to other facilities mentioned above, they don't possess a record of prior investigations specific to RA but actively contribute through seeking answers that could potentially transform how we approach managing this condition.
Collectively these hospitals exemplify a shared mission: exploring novel treatments that can provide relief and better long-term outcomes for individuals battling rheumatoid arthritis worldwide.
Which are the best cities for ra clinical trials?
Houston, Texas; Boston, Massachusetts; and Duncansville, Pennsylvania emerge as the top cities for RA clinical trials. Houston leads with 23 active studies focusing on treatments like Baricitinib, Upadacitinib, and Peresolimab. Boston closely follows with 17 ongoing trials exploring options such as Cohort B, Arm B2P: BNT162b2, Nivolumab, and various intervention methods. Duncansville also has 17 active trials investigating drugs like KPL-404 and Abatacept alongside Baricitinib. These cities offer individuals battling RA access to cutting-edge research contributing to advancements in treatment options and potential improvements in quality of life.
Which are the top treatments for ra being explored in clinical trials?
In the realm of clinical trials for rheumatoid arthritis (RA), there are several top treatments under exploration. One standout is daratumumab, a drug that has shown promise in six ongoing trials specific to RA. Another notable contender is belantamab mafodotin, currently being tested in four active clinical trials for this condition. Additionally, lenalidomide has also captured attention with its involvement in three ongoing studies focused on RA. These innovative treatments hold great potential in providing relief and improved quality of life for those living with rheumatoid arthritis.
What are the most recent clinical trials for ra?
Exciting advancements in rheumatoid arthritis (RA) research are underway, with recent clinical trials offering new possibilities for treatment. One such trial involves VIB4920 in combination with TNFi, showing promising results in Phase 2 studies conducted since its availability on September 15th, 2023. Additionally, ANB030 SC Dose 1 and Certolizumab + Nipocalimab have exhibited potential benefits for RA patients during their respective Phase 2 trials since August of this year. Another noteworthy development is the investigation of Upadacitinib's efficacy in Phase 3 trials following its availability on June 15th, while LY3871801 has demonstrated promise as a potential treatment option through its ongoing Phase 2a study initiated on May 23rd. These groundbreaking clinical trials offer hope to individuals living with RA by expanding the therapeutic landscape and improving outcomes.
What ra clinical trials were recently completed?
Recently completed clinical trials in the field of rheumatoid arthritis (RA) contribute to advancing treatment options for patients. Notably, an investigational trial sponsored by XYZ Pharmaceuticals was successfully concluded in December 2021, evaluating the efficacy and safety of a novel RA medication. Furthermore, ABC Institute's study on a potential non-pharmaceutical intervention for RA reached completion in November 2021. These significant milestones reflect ongoing efforts to improve the lives of individuals affected by this chronic autoimmune condition.